Paragon 28 Inc (FRA:7GQ)

€ 9.35 0 (0%) Market Cap: 792.44 Mil Enterprise Value: 860.09 Mil PE Ratio: 0 PB Ratio: 6.01 GF Score: 34/100

Q3 2024 Paragon 28 Inc Earnings Call Transcript
Nov 12, 2024

€7 (+10.24%)

Earnings
Q2 2024 Paragon 28 Inc Earnings Call Transcript
Aug 08, 2024

€7.2 (+5.11%)

Earnings
Q1 2024 Paragon 28 Inc Earnings Call Transcript
May 08, 2024

€9.65 (-1.03%)

Earnings
Q4 2023 Paragon 28 Inc Earnings Call Transcript
Feb 29, 2024

€11 (+0.92%)

Earnings
Paragon 28 Inc at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Q3 2023 Paragon 28 Inc Earnings Call Transcript
Nov 07, 2023

€9.1 (-2.15%)

Earnings
Paragon 28 Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Paragon 28 Inc at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023
Q2 2023 Paragon 28 Inc Earnings Call Transcript
Aug 02, 2023

€15.4 (-3.14%)

Earnings
Paragon 28 Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Q1 2023 Paragon 28 Inc Earnings Call Transcript
May 04, 2023

€16.5

Earnings
Q4 2022 Paragon 28 Inc Earnings Call Transcript
Mar 02, 2023

€16.4 (+0.61%)

Earnings

Paragon 28 Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 11:00PM GMT

Release Date Price: €10.7

Transcript 8-K

Lisa Cohen J.P. Morgan Securities LLC;Analyst

Good afternoon, everyone, and welcome to the 42nd Annual J.P. Morgan Healthcare Conference. My name is Lisa Cohen. I am a Vice President in San Francisco, and I sit in the healthcare investment banking group. Very excited to introduce our next company, Paragon. With me here today are Albert DaCosta, CEO, and Steve Deitsch, CFO. So with that, I will pass it on to them.

Albert DaCosta Paragon 28 Inc.;Chairman of the Board

President & CEO

Thank you. All right.

Thank you. Thanks for having us. It's great to see everybody here. I'm going to warn you ahead of time. That I might have a little bit of a coughing fit. If I do, I'm going to pass it over to Steve. Let's get started.

First thing, the story might be new for some of the folks here on. One thing I'd like to start off with is just kind of explaining a little bit about the foot and ankle market and that image there doesn't show any of the soft tissue structures. But if you think about from a skeletal perspective, the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.